|August 1, 2021||Abstract Submission Site Opens|
|November 1, 2021||Abstract Submission Deadline*|
|December 17, 2021**||Abstract Acceptance Notifications|
|January 14, 2021||Deadline to Accept Presentation in Program and Register for IMAST|
*Abstracts with authors missing completed Conflict of Interest Disclosures will NOT be reviewed.
**Date tentative and subject to change
Abstracts must be submitted by Monday, November 1, 2021. No exceptions will be made.
Abstracts submitted to the 29th IMAST must fit into one of the following categories to be considered for presentation:
- Adolescent Idiopathic Scoliosis
- Adult Spinal Deformity
- Basic Science/Biomechanics/Genetics
- Cervical Deformity
- Cervical Degenerative/Reconstruction*
- Early Onset Scoliosis
- Innovative Methods*
- Lumbar Degenerative*
- Minimally Invasive Surgery*
- Miscellaneous (Spondy, Trauma, Tumor, etc.)
- Motion Preservation*
- Neuromuscular/Syndromic Deformity
- Non-Op Treatment Methods
*IMAST Only Categories
By submitting an abstract to IMAST abstract authors are agreeing that at least one author will attend the meeting for which the abstract is accepted and will be available to present on the date and at the time assigned by the organizing committees. Authors will be notified of presentation times at the time of or shortly after notification of acceptance and are expected to make appropriate travel arrangements to ensure that at least one of the abstract’s authors will be in attendance. In addition, presenting authors are expected to register to attend the meetings for which they are accepted by the deadline set forth in their acceptance notification. Abstracts for which an author is not pre-registered by the dates set forth with automatically be withdrawn from the program.
All selected authors will be required to complete a formal acceptance process by January 14, 2022 to confirm the invitation to participate in the program.
Oral Presentation Cancellation & No-Show Policy
If an author or co-author is not able to attend the meeting to present a paper in person, it is expected that an abstract be withdrawn in advance of the meeting (by February 1, 2022) so that an alternate paper may be substituted. In the case of a “no-show” oral presentation, please note that the presenting author associated with the “no-show” paper will be prohibited from presenting any papers at the next two IMAST Meetings.
E-Poster Cancellation Policy
At least one author or co-author on all E-Posters are expected to register to attend the meetings for which they are accepted by the deadline set forth in their acceptance notification. If this author cancels their registration prior to the meeting, the E-Poster may be withdrawn from the program.
Advance Presentation Submission Requirement
All presentations must clear a CME review conducted by the SRS CME Committee. Presenters may be required to submit slides for review before the meeting and may be asked to make small or significant changes if a bias issue is found. Failure to address pertinent CME review issues will result in pulling the presentation from the program and in a one-year ban for abstract presentations and a three-year ban for invited presentations.
The 29th IMAST will be comprised of the latest science in the field, presented as paper (podium) presentations, E-Posters, symposia of invited lecturers, debates, and case discussions. Presenters will represent the best of the SRS membership, as well as non-members, from an international group of physicians and researchers. The Scientific Papers and E-Posters will be selected by the IMAST Committee, based on a blinded review of submissions.
The scientific content of IMAST will focus on innovative technologies, new surgical techniques, emerging challenges and solutions. The IMAST Committee will select abstracts and give priority to these topics as well as others deemed "innovative" in order to foster a distinct feel and purpose of IMAST.
Ideal topics for IMAST include: new surgical techniques, outcomes and methods of robotics and navigation technologies, changes in healthcare economics and cost pressures resulting in changes in practice, the utility of artificial intelligence and “big data” algorithms that will foster innovative care for all pathologies of the spine. We encourage the use of control groups to optimize the science associated with evaluating these new technologies, but clinical follow up may be as short as one (1) year for clinical series submitted to IMAST.
- Program focused on innovative and new methods/techniques for treating spinal pathology beyond deformity
- Program divided equally between adult deformity; pediatric deformity; degenerative lumbar and cervical pathology
- Features Free Papers, Hands-On Workshops, Roundtable discussions, Debates, Video techniques, Complication series, and Instructional Course Lectures, E-Posters
- 2.5 - day program, including papers, commercial exhibits, and demonstrations
- One-year clinical follow-up required for free paper submissions
- Topics focus on new and advanced techniques for treating a wide range of spinal conditions
Who Should Attend?
The 29th IMAST is open to anyone involved in the treatment of spinal disorders including spine surgeons, residents and fellows, physician assistants, nurses and other allied health professionals, and researchers. The presentations selected will provide valuable information to all individuals caring for patients with spinal deformities.
Abstracts must be submitted online via the IMAST website (https://owpm1.com/abstracts/IMAST). Complete instructions for submission are on this webpage. The submission site will only take submissions for IMAST.
Abstract Review Process
- All abstracts submitted will be reviewed and graded in blinded fashion by the IMAST Committee.
- One-year follow-up is required for papers submitted to IMAST.
- Based upon abstract grading, those selected will be assigned to a four-minute oral presentation or E-Poster.
- The review process takes approximately 8 weeks, and acceptance notification will be made by email by December 17, 2021.
Disclosure and Licensing Requirement
All abstract authors will be required to submit a Financial Disclosure Statement, an FDA Disclosure Form, an Attestation, and Non-Exclusive Licensing Agreement during the online submission process. ALL authors listed on an abstract will be required to submit a financial disclosure form, including disclosure of ALL financial relationships, not only those pertaining to the topic of the abstract. In the event that all authors on an abstract have not completed these required forms prior to the submission deadline of November 1, 2021, the abstract will NOT be reviewed or considered for inclusion in the IMAST.
Visit this link to disclose: https://www.owpm1.com/abstracts/IMAST/disclosure
The username is the email associated with your abstract and the password your first name.
Study Design Questions
The questions regarding study design will be available to the reviewers and may be shown as part of the disclosure slide if the abstract is accepted for presentation. It is highly encouraged these questions be completed when submitting an abstract.
Previous Publication or Presentation
Abstracts which have been published in journals, meeting proceedings, or other publication, as well as those presented at meetings prior to the SRS meeting to which authors wish to submit, are NOT eligible for submission. Only abstracts that have NOT been previously published or presented are eligible for submission.
The term “hardware” should not be used in written abstract submissions, oral presentations, and E-Poster presentations. The terms “instrumentation,” “implants,” “constructs,” or “montage” should be used instead.
Specific instrumentation such as “Isola, TSRH, CD, XLIF, DLIF, AxiaLIF, Solera, Vertex, Expedium, Mountaineer, Shilla, VEPTR, etc.,” should not be used in presentations. These terms should be replaced by a generic description of the instrumentation or technique unless the use of the term directly impacts learners’ understanding of the presentation or data. Instrumentation may also be referred to when the device name is a landmark system that is no longer sold (i.e. Harrington, Cotrel-Dubousset, Luque). Company names and logos must never be used in a presentation.
It is recognized that studies evaluating a device or devices or comparing different devices or techniques may require the use of product or technique names. If a device trade name or industry developed technique using a trademarked name are used in an abstract or presentation, it will be specifically reviewed by the CME Committee for evaluation of any potential conflict of interest. When there is a known potential conflict of interest, an expanded verbal disclosure will be necessary at the time of presentation. Furthermore, if a product name is mentioned, the audience should be informed of why it is necessary to give the name.
For questions about abstracts, please contact the SRS Education team at firstname.lastname@example.org.